MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients suffering from Gram-negative, MBL-resistant infections Meropenem resistance in India is as high as 62-87%, with up to 50% linked to MBL prevalence, according to ICMR